Fig. 1From: An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 studyStudy flow diagram. *Includes two patients with wild-type ATTR; one patient with hereditary ATTR. AA, serum amyloid A; ApoAI, apolipoprotein A-I; AFib; fibrinogen-a alpha chain; AL, immunoglobulin light chain; ATTR, transthyretinBack to article page